Biophan Technologies, Inc (BIPH) Fair Value & Analysis
Healthcare · US · Market cap $358K
Biophan Technologies, Inc
BIPH · US
Fair value as of: Jul 9, 2026
From 14 valuation models · updated today
Fair value updated Jul 9, 2026 — revised from $1,135,668 to $16.81 (−100.0%) since Jun 24, 2026. Share price −0.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $14.81 – $16.67 · fair‑value band $12.61 – $21.01 · the $16.00 price screens below the $16.81 fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Biophan Technologies, Inc (BIPH) currently trades at $16.00, while our model-based Fair Value estimate is $16.81 — implying the stock looks roughly 5.1% undervalued today. We read business quality at 50/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Trailing-twelve-month revenue stands at $678K. Revenue grew 17.1% year over year. Net debt stands at $66.3B. Fundamentals as of Jul 9, 2026
Our scenario range runs from $12.61 (bear case) to $21.01 (bull case); at $16.00, the current price sits within that range. The share trades about 5% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside — at 5%, BIPH screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
Biophan Technologies, Inc. develops and markets various technologies for the medical device industries. The company is seeking partners to monetize its patented technologies, including biothermal power supply and pulsewidth modulation technology to enhance the performance of pacemakers and neurostimulators, and photonics and nanomaterials patents. The company was founded in 1963 and is based in Pittsford, New York.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Biophan Technologies, Inc reported revenue of $23.1B in FY2026 versus $11.5B in FY2022, a compound +19.0%/yr. Reported net income was $449M in FY2026, compounding −7.5%/yr from FY2022.
Is BIPH fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| Becton, Dickinson and Company BDX | $143.92 | $104.17 | -28% |
| Alcon Inc ALC | $66.11 | $36.99 | -44% |
| ResMed Inc R1MD34 | R$253.26 | R$41.40 | -84% |
| West Pharmaceutical Services, Inc WST | $329.71 | $137.28 | -58% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $13.07 | $5.51 | -58% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Biophan Technologies, Inc (BIPH) undervalued?
What is the fair value of BIPH?
What is the quality score of BIPH?
What is the revenue of Biophan Technologies, Inc (BIPH)?
What is the net profit margin of BIPH?
Does Biophan Technologies, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
The 25 strongest value stocks, free every month
Enter your email to get the free monthly Top-25 report of the most undervalued quality stocks from 35,000+ analysed. Unsubscribe anytime.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.